COVID Vaccine Efficacy Wanes, Boosters Essential for Sustained Protection

The rapid development and deployment of mRNA and adenoviral vector COVID-19 vaccines represented an unprecedented scientific achievement. These vaccines demonstrated remarkable efficacy in preventing symptomatic infection, hospitalisation, and death in large-scale clinical trials.¹ Initial data from real-world observational studies mirrored these trial results, showing vaccine effectiveness against symptomatic disease often exceeding 90% in the months immediately following the primary series.² This high level of protection provided a critical tool in mitigating the pandemic's impact, allowing for a gradual return to normalcy in many regions.

But the SARS-CoV-2 virus proved adept at evolving, with new variants emerging that presented challenges to vaccine-induced immunity. Concerns about waning immunity and reduced vaccine effectiveness against these variants, particularly Delta and Omicron, began to surface as early as six months post-vaccination.³ Public health agencies and researchers initiated extensive observational studies to quantify this decline and understand its clinical implications. These studies often leveraged national health registries and large population cohorts, providing robust real-world evidence on vaccine performance over time.

The numbers on waning immunity

Multiple large-scale observational studies consistently demonstrated a decline in vaccine effectiveness against SARS-CoV-2 infection and symptomatic disease over time. For instance, a study in the UK involving over 3.5 million individuals showed that effectiveness against symptomatic infection for the Pfizer-BioNTech BNT162b2 vaccine dropped from 88% (95% CI, 87-89%) one month after the second dose to 74% (95% CI, 73-76%) five to six months later.⁴ The AstraZeneca ChAdOx1 nCoV-19 vaccine showed a similar pattern, with effectiveness against symptomatic infection decreasing from 77% (95% CI, 76-78%) to 67% (95% CI, 65-69%) over the same period.⁴

This waning was more pronounced against infection than against severe outcomes. A study from Israel, published in the New England Journal of Medicine, found that among individuals aged 60 years or older, the rate of confirmed infection was 11.3 times higher (95% CI, 10.4-12.3) in those who received two doses at least five months prior compared to those who received a booster dose.⁵ The rate of severe disease was 19.5 times higher (95% CI, 12.9-29.5) in the two-dose group.⁵ These figures underscored the critical role of booster doses in restoring high levels of protection, particularly for vulnerable populations.

The emergence of the Omicron variant further complicated the picture, as its numerous spike protein mutations allowed it to partially evade vaccine-induced immunity. Data from Qatar, published in the New England Journal of Medicine, indicated that two doses of the Pfizer-BioNTech vaccine offered only 34.7% (95% CI, 25.4-42.6%) effectiveness against symptomatic Omicron infection within the first two months, dropping further to 10.4% (95% CI, -5.5-24.0%) after four to six months.⁶ A booster dose, however, significantly improved this, raising effectiveness to 52.2% (95% CI, 47.9-56.1%) in the first two months post-booster.⁶ Protection against severe disease remained more durable, but still benefited from boosting.

The mechanism behind this waning immunity is multifactorial. It involves a natural decline in antibody titres over time, particularly neutralising antibodies that block viral entry.⁷ Memory B cells and T cells, which provide longer-term protection, also play a role, but their activation and expansion are often boosted by additional antigen exposure.⁷ The open-label nature of many real-world observational studies is an obvious caveat, as confounding factors related to health-seeking behaviour or differential exposure cannot be entirely eliminated. Still, the consistency of findings across diverse populations and vaccine types lends considerable weight to the conclusion that vaccine protection diminishes over several months.

These studies, while not randomised controlled trials, provided essential evidence for public health policy decisions regarding booster campaigns. They demonstrated that while the primary series offered substantial initial protection, particularly against severe outcomes, maintaining optimal defence against infection and symptomatic disease, especially with new variants, required periodic re-stimulation of the immune system. The data consistently supported the strategy of offering booster doses to eligible populations to sustain high levels of population immunity and reduce the burden on healthcare systems. The trial was not powered to detect differences in very rare adverse events, and that gap matters for public confidence.